Results 1 to 10 of about 23,127 (334)
Physiological Reports, 2019 Bariatric surgery is now the most widely used intervention for the treatment of human obesity. A large body of literature has demonstrated its efficacy in sustained weight loss and improvement in its associated comorbidities.
Isabel Casimiro +2 more
exaly +3 more sources
Endokrynologia Polska, 2021 INTRODUCTION: The effect of incretins including dipeptidyl peptidase 4 inhibitors (DPP4-Is) and glucagon-like peptide1 receptor agonists (GLP1-ras) in the treatment of type 2 diabetes increasing the risk of fracture remains controversial.
Qing-xin Kong +5 more
doaj +2 more sources
Incretins in obesity and diabetes
Annals of the New York Academy of Sciences, 2020 Incretins are hormones secreted from enteroendocrine cells after nutrient intake that stimulate insulin secretion from β cells in a glucose‐dependent manner.
Chee W Chia, Josephine M Egan
exaly +2 more sources
Incretins in the Therapy of Diabetic Kidney Disease
International Journal of Molecular Sciences, 2021 Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality.
Agnieszka +2 more
exaly +2 more sources
Clinical Pharmacology: Advances and Applications, 2018 Simone Perna,1 Manuela Mainardi,2 Paolo Astrone,2 Carlotta Gozzer,3 Anna Biava,1 Ruben Bacchio,3 Daniele Spadaccini,3 Sebastiano Bruno Solerte,2 Mariangela Rondanelli4 1Department of Biology, College of Science, University of Bahrain, Sakhir Campus ...
Perna S +8 more
doaj +2 more sources
Bile acids and incretins as modulators of obesity-associated atherosclerosis [PDF]
Frontiers in Cardiovascular MedicineObesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic ...
Andrijana Kirsch +4 more
doaj +2 more sources
Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection [PDF]
Frontiers in MedicineEndothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Allegra Battistoni +5 more
doaj +2 more sources
Do incretins improve endothelial function? [PDF]
Cardiovascular Diabetology, 2014 An impaired endothelial function has been recognized in the early stage of atherosclerosis, and is a major factor affecting the future development of cardiovascular events.
Jun-ichi Oyama +2 more
core +2 more sources
Pharmaceutics, 2023 Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2 diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated to play a markedly protective role for the cardiovascular system beyond ...
ylenia la porta +2 more
exaly +3 more sources
Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
Health Sciences Review, 2023 Diabetes mellitus and osteoporosis are chronic illnesses associated with adverse health outcomes. Studies have reported common linkages between energy and bone metabolism.
Faraha Ahmed +8 more
doaj +1 more source